Fanni Natanegara

Learn More
Accumulating evidence suggests that the primary symptoms of schizophrenia may be associated with altered central glutamate transmission. LY2140023 monohydrate is the methionine prodrug of the selective mGlu2/3 receptor agonist LY404039 and is currently being assessed for the treatment of schizophrenia. The objective of this study was to evaluate the central(More)
BACKGROUND Prasugrel is an oral antiplatelet agent approved for the reduction of atherothrombotic cardiovascular events in patients presenting with acute coronary syndrome and undergoing percutaneous coronary intervention. Although the approved loading dose is 60 mg, earlier studies of prasugrel suggested that active-metabolite exposure and pharmacodynamic(More)
OBJECTIVES To evaluate patient and female partner responses on the efficacy of, and overall satisfaction with, tadalafil to treat erectile dysfunction using sexual encounter profile (SEP) diaries. METHODS Data were pooled from four double-blind, placebo-controlled, 12-week trials that included 746 couples. Patients were randomized to placebo or tadalafil(More)
AIMS This open-label, two-period, randomized, crossover study was designed to determine the effect of CYP2C19 reduced function variants on exposure to active metabolites of, and platelet response to, prasugrel and clopidogrel. METHODS Ninety healthy Chinese subjects, stratified by CYP2C19 phenotype, were randomly assigned to treatment with prasugrel 10 mg(More)
INTRODUCTION Limited efficacy and safety data exist from open-label clinical trials of phosphodiesterase 5 inhibitors in men with erectile dysfunction (ED) and multiple comorbid (MCM) conditions, historically a difficult group to treat. AIM A multicenter study (Multiple Observations in Men with Erectile Dysfunction in National Tadalafil Study in the US)(More)
OBJECTIVE To determine whether patients with erectile dysfunction (ED) and treated with tadalafil use the 36-h duration of effect of the drug, and to discern if the timing of intercourse attempts is influenced by patient age, baseline severity of ED, or previous experience with sildenafil citrate. PATIENTS AND METHODS In 11 multicentre, double-blind,(More)
To show that tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction (ED) and efficacy is noninferior to that in Caucasian men. Multiple observations in men with ED in national tadalafil study in the US, a multicenter, open-label study, assessed the efficacy of tadalafil 20 mg taken as needed (maximum one dose/day before sexual(More)
AIM This U.S. multicenter open-label study used a noninferiority trial design to assess the efficacy of tadalafil 20 mg to treat erectile dysfunction (ED) in the black American and Hispanic groups compared with a reference group of Caucasians. A secondary objective was to demonstrate the efficacy and safety of tadalafil 20 mg in various populations of men(More)
This retrospective analysis examined the daily/weekly patterns of sexual activity, by age and marital status, of men with erectile dysfunction (ED) participating in a 12-week, multicenter, open-label study of tadalafil (20 mg) as needed. The timing of intercourse attempts post dose and satisfaction were assessed using the Sexual Encounter Profile diary.(More)
INTRODUCTION Erectile dysfunction is increasingly common with advancing age, yet sexual activity and intimacy are important to elderly men. AIM To assess the efficacy and tolerability of tadalafil in men over the age of 65 years. METHOD In this multicenter open-label study, 188 men (mean age = 71.6 years) who were over age 65 and did not have diabetes(More)